|
Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation Clinical research trials and Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation. Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation clinical trial. Subjects frequently get the best healthcare possible for their Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation  Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation
Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation
For Condition: recurrent adult non-Hodgkin's lymphoma,recurrent childhood acute lymphoblastic leukemia,recurrent adult acute myeloid leukemia,Graft Versus Host Disease,refractory chronic lymphocytic leukemia,recurrent childhood lymphoblastic lymphoma,recurrent childhood acute myeloid leukemia,refractory chronic myelogenous leukemia,childhood non-Hodgkin's lymphoma,recurrent adult acute lymphoblastic leukemia
Status: Completed
Sponsor(s): Fred Hutchinson Cancer Research Center ,
Synopsis: RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against normal tissues. Methotrexate and cyclosporine may prevent this from happening. PURPOSE: Phase III trial to study the effectiveness of treatment with methotrexate and cyclosporine after bone marrow transplantation to provide protection against acute graft-versus-host disease.
Details: OBJECTIVES: I. Determine the efficacy of a combination of methotrexate and cyclosporine, administered after grafting, to prevent the development of acute graft versus host disease (GVHD) in patients undergoing allogeneic bone marrow transplantation. PROTOCOL OUTLINE: Patients receive methotrexate IV on days 1,3,6, and 11. Patients also receive cyclosporine IV twice a day until the patient is eating, then it is administered orally twice a day. Cyclosporine begins on day -1 and continues until day 180. The dose is reduced beginning on day 50. PROJECTED ACCRUAL: Accrual will continue until further notice.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Ongoing bone marrow transplantation from HLA-matched siblings or HLA non-identical family members or unrelated donor --Prior/Concurrent Therapy-- - No concurrent experimental treatment on other GVHD prophylaxis studies --Patient Characteristics-- - Age: Any age - Performance status: Not specified - Life expectancy: Not severely limited by disease other than leukemia - Hematopoietic: Not specified - Hepatic: No severe hepatic disease - Renal: No history of hemorrhagic cystitis; No renal disease - Cardiovascular No symptomatic cardiac disease - Other: No contraindication to the use of cyclosporine or methotrexate
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RainerStorb, Study Chair, Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
United States
Additional Information:
Study ID Numbers: CDR0000074146; FHCRC-267.01,NCI-V86-0145,FHCRC-267.00
Study Start Date: May 1986
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002456
Other Recurrent Childhood Acute Myeloid Leukemia Studies:
1. Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation
Related Studies:
Other recurrent childhood acute myeloid leukemia Clinical Trials
Other Washington Clinical Trials
Other Seattle Clinical Trials
Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation
|
|
|
|
|
|
|
|
